Robert Kramer - Emergent Biosolutions President
| EBS Stock | USD 7.27 0.06 0.83% |
President
Mr. Robert G. Kramer Sr., is re designated as President, Chief Executive Officer, Director of the Company since April 2019. He served as our president and chief operating officer from March 2018 to March 2019. Previously, he also served as our executive vice president, administration, chief financial officer and treasurer from September 2012 until his promotion to president and chief operating officer in March 2018. Mr. Kramer first joined us in 1999 as our chief financial officer. From 1999 until his prior retirement in 2010, he held various executive positions with the last being president of Emergent Biodefense Operations Lansing. Mr. Kramer returned to the company in 2011 as the interim head of the biosciences division, and then as interim executive vice president, corporate services division. Prior to joining us in 1999, Mr. Kramer held various financial management positions at Pharmaci Corporationrationration, which subsequently merged with the Upjohn Company in 1995 and eventually became part of Pfizer Inc since 2019.
| Age | 62 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Phone | 240 631 3200 |
| Web | https://www.emergentbiosolutions.com |
Robert Kramer Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Kramer against Emergent Biosolutions stock is an integral part of due diligence when investing in Emergent Biosolutions. Robert Kramer insider activity provides valuable insight into whether Emergent Biosolutions is net buyers or sellers over its current business cycle. Note, Emergent Biosolutions insiders must abide by specific rules, including filing SEC forms every time they buy or sell Emergent Biosolutions'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Kramer over two weeks ago Acquisition by Robert Kramer of 7500 shares of Appian Corp subject to Rule 16b-3 |
Emergent Biosolutions Management Efficiency
The company has Return on Asset of (0.0422) % which means that on every $100 spent on assets, it lost $0.0422. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3464) %, meaning that it generated no profit with money invested by stockholders. Emergent Biosolutions' management efficiency ratios could be used to measure how well Emergent Biosolutions manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Roman Trawicki | Zoetis Inc | 56 | |
| John Condon | Intracellular Th | N/A | |
| Glenn David | Zoetis Inc | 52 | |
| Scott Dreyer | Collegium Pharmaceutical | 53 | |
| Catherine Knupp | Zoetis Inc | 59 | |
| David Gaffin | Alkermes Plc | 52 | |
| Parker Javid | Lifecore Biomedical | 56 | |
| Joseph Ciaffoni | Collegium Pharmaceutical | 53 | |
| Wetteny Joseph | Zoetis Inc | 52 | |
| Christina Ackermann | Bausch Health Companies | 55 | |
| William PPool | Prestige Brand Holdings | 59 | |
| Shirley Kuhlmann | Collegium Pharmaceutical | 40 | |
| Heidi Chen | Zoetis Inc | 57 | |
| Mark Neumann | Intracellular Th | 61 | |
| Paul Herendeen | Bausch Health Companies | 65 | |
| Michael Olchaskey | Intracellular Th | N/A | |
| Robert Davis | Intracellular Th | 74 | |
| Michael Landine | Alkermes Plc | 70 | |
| Joseph Gordon | Bausch Health Companies | 56 | |
| Sherry Pudloski | Zoetis Inc | 52 | |
| Roxanne Lagano | Zoetis Inc | 60 | |
Management Performance
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.0422 |
Emergent Biosolutions Leadership Team
Elected by the shareholders, the Emergent Biosolutions' board of directors comprises two types of representatives: Emergent Biosolutions inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Emergent. The board's role is to monitor Emergent Biosolutions' management team and ensure that shareholders' interests are well served. Emergent Biosolutions' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Emergent Biosolutions' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kelly Warfield, Senior Development | ||
| Sean Kirk, Executive Vice President - Manufacturing and Technical Operations | ||
| William Hartzel, Senior Bioservices | ||
| Robert Burrows, IR Contact Officer | ||
| Stephanie Duatschek, Chief VP | ||
| Sue Bailey, Independent Director | ||
| Jerome Hauer, Independent Director | ||
| Haywood Miller, Interim Officer | ||
| Kathryn Zoon, Independent Director | ||
| Seamus Mulligan, Director | ||
| George Joulwan, Independent Director | ||
| Karen Smith, Executive Vice President Chief Medical Officer | ||
| Paul Williams, Senior Business | ||
| Keith Katkin, Independent Director | ||
| Simon MD, Chief Development | ||
| Jessica Perl, Corporate Counsel | ||
| Robert Kramer, CFO, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer | ||
| Richard MBA, CFO VP | ||
| Jennifer Fox, Executive Vice President - External Affairs, General Counsel, Corporate Secretary | ||
| Katherine Strei, Executive Vice President - Human Resources and Communications, Chief Human Resources Officer | ||
| Michelle Pepin, Senior Officer | ||
| Fuad ElHibri, Executive Chairman of the Board | ||
| Coleen Glessner, Executive Compliance | ||
| Lynn Kieffer, VP Communications | ||
| Joseph Papa, CEO President | ||
| Marvin White, Director | ||
| Atul Saran, Executive Vice President Corporate Development, General Counsel and Corporate Secretary | ||
| Robert Sr, Pres CEO | ||
| Adam Havey, Executive VP and President of Biodefense Division | ||
| Louis Sullivan, Independent Director | ||
| Ronald Richard, Lead Independent Director | ||
| Zsolt Harsanyi, Non-Executive Independent Chairman of the Board | ||
| Richard Lindahl, Chief Financial Officer, Executive Vice President, Treasurer |
Emergent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Emergent Biosolutions a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.0422 | ||||
| Profit Margin | (0.19) % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 900.66 M | ||||
| Shares Outstanding | 54.18 M | ||||
| Shares Owned By Insiders | 2.15 % | ||||
| Shares Owned By Institutions | 57.78 % | ||||
| Number Of Shares Shorted | 6.95 M | ||||
| Price To Earning | 1.67 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.